Versigent PLC filed its Form 10-Q with the SEC on November 4, 2026, covering the quarterly period ended September 30, 2026, disclosing revenue growth, a significant increase in long-term debt, and ongoing restructuring and separation costs.

Key Highlights

  • Net sales of $2,450 million for the three months ended September 30, 2026, compared with $2,286 million in the same period of 2025, according to the filing.
  • Net income attributable to Versigent was $102 million for the three months ended September 30, 2026, versus $109 million in the prior-year quarter.
  • Long-term debt rose to $2,066 million as of September 30, 2026, compared with $3 million as of December 31, 2025, as reported on the condensed consolidated balance sheet.
  • Separation costs of $59 million were recorded for the nine months ended September 30, 2026, up from $14 million in the same period of 2025.
  • Diluted earnings per share attributable to Versigent were $1.41 for the three months ended September 30, 2026, compared with $1.54 in the prior-year period.
  • Cash and cash equivalents increased to $638 million as of September 30, 2026, from $276 million as of December 31, 2025.
  • 70,844,658 ordinary shares were outstanding as of October 30, 2026, the filing states.

Versigent PLC's Third-Quarter 2026 Financial Results and Balance Sheet Changes

Versigent PLC (NYSE:VGNT), a Jersey-incorporated company headquartered in Schaffhausen, Switzerland, reported net sales of $2,450 million for the three months ended September 30, 2026, an increase from $2,286 million in the comparable period of 2025, according to the unaudited condensed consolidated statements of operations included in the filing. For the nine months ended September 30, 2026, net sales reached $7,106 million, compared with $6,516 million in the nine months ended September 30, 2025.

Operating income for the three months ended September 30, 2026 was $185 million, up from $164 million a year earlier, the filing disclosed. Total operating expenses for that quarter were $2,265 million, which included cost of sales of $2,120 million, selling, general and administrative expenses of $112 million, restructuring charges of $22 million, and separation costs of $11 million. Interest expense for the three months ended September 30, 2026 was $36 million, compared with zero in the same quarter of 2025. For the nine months ended September 30, 2026, interest expense was $77 million, versus $3 million in the prior-year nine-month period, as reported in the filing.

The condensed consolidated balance sheet shows that long-term debt stood at $2,066 million as of September 30, 2026, compared with $3 million as of December 31, 2025. Total shareholders' equity declined to $363 million as of September 30, 2026, from $1,848 million as of December 31, 2025. The filing also notes that the company's equity structure shifted during the period: as of December 31, 2025, the balance sheet reflected a "Former Parent's net investment" of $1,925 million, while as of September 30, 2026, the company shows ordinary shares, additional paid-in capital of $144 million, and retained earnings of $211 million, reflecting its status as a standalone public entity. Share-based compensation of $28 million was recorded for the nine months ended September 30, 2026, compared with $24 million in the same period of 2025.

What Was Disclosed

Versigent PLC filed a quarterly report on Form 10-Q for the period ended September 30, 2026, disclosing revenue, earnings, balance sheet data, and cash flow information for the three and nine months ended September 30, 2026 and 2025, along with notes on restructuring, separation costs, and changes in debt and equity structure.